KCTD9 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HAP1 near-haploid cell line, engineered to disrupt the KCTD9 gene. This polyclonal pool offers a heterogeneous loss-of-function model, enabling functional analysis of KCTD9 without single-cell cloning. The targeted disruption eliminates KCTD9 protein expression across the population, providing a robust tool for studying its role in ubiquitin-mediated signaling and immune regulation. Researchers can utilize these cells to investigate downstream consequences of KCTD9 deficiency in a controlled in vitro setting, benefiting from the genetic simplicity of the host line.
The parental HAP1 cell line is a near-haploid chronic myeloid leukemia (CML) line, originally derived from the KBM-7 patient, and is characterized by a predominantly haploid karyotype except for disomy of chromosome 8. These adherent, fibroblast-like cells are extensively employed in haploid genetic screens due to the ease of generating loss-of-function mutations. Their robust growth characteristics and responsiveness to cytokines make them suitable for dissecting signaling pathways. The near-haploid background enhances the penetrance of gene disruption, allowing clear observation of phenotypic changes upon KCTD9 knockout, particularly in pathways dependent on ubiquitination and transcriptional regulation.
KCTD9 functions as a substrate adaptor for the Cullin-3 (CUL3)-RING E3 ubiquitin ligase complex, facilitating the ubiquitination and proteasomal degradation of target proteins such as TRAF6. By promoting TRAF6 turnover, KCTD9 negatively regulates NF-??B signaling and the production of pro-inflammatory cytokines including IL-6 and TNF. Upstream, KCTD9 expression is modulated by IFNG, IL-2, TLR ligands, and TNF. In the absence of KCTD9, TRAF6 accumulates, leading to enhanced NF-??B activity and transcriptional activation of inflammatory mediators. Additionally, KCTD9 influences adaptive immunity by controlling NK and CD8+ T cell activation, with downstream effectors such as PRF1 and GZMB being derepressed. The pathway involves key components like CUL3, RBX1, TRAF6, NFKBIA, and RELA.
In the HAP1 context, KCTD9 disruption provides a simplified model to study the molecular determinants of ubiquitin ligase adaptor function and inflammatory signaling. The haploid nature reduces genetic redundancy, magnifying the impact of KCTD9 loss on NF-??B-driven responses. This system is particularly valuable for examining cross-talk between interferon signaling and innate immune regulators, as HAP1 cells respond to cytokine stimulation. The polyclonal format captures a range of genetic perturbations, allowing assessment of population-level responses and functional heterogeneity, which is beneficial for pharmacological modulation studies. The knockout population serves as a platform to screen for compounds that modulate CUL3-dependent pathways.
These cells are ideally suited for a spectrum of research applications, including functional studies of ubiquitin ligase adaptors, immune cell signaling, inflammation and autoimmune disease modeling, and drug target screening for immune disorders. Representative assays include Western blot to assess protein expression changes, co-immunoprecipitation to probe interaction partners like CUL3 and TRAF6, and NF-??B reporter assays to measure transcriptional activity. Cytokine ELISA and flow cytometry for CD69 and NK cell activation markers can quantify immune effector readouts. Transcriptomic analyses via RT-qPCR and RNA-seq enable global gene expression profiling. For further technical details, please contact Ascent Research.
